Fludarabine Phosphate 50mg/2mL (25mg/mL) Injection

Product Introduction

Fludarabine Phosphate 50mg/2mL (25mg/mL) is a purine-analogue chemotherapy used for B-cell chronic lymphocytic leukaemia and selected haematology regimens. It acts on abnormal lymphocytes in the blood and bone marrow.

How to use

The prepared dose is administered into a vein on the scheduled treatment days, commonly as a short infusion. Dose and cycle timing depend on kidney function, blood counts and the combination regimen.

How it works

Fludarabine is converted to an active nucleotide that interferes with DNA formation and repair, leading to death of susceptible lymphocytes.

Side effects

Low blood counts, nausea, fatigue and fever can occur. Serious opportunistic infections, autoimmune haemolytic anaemia and neurological toxicity are important risks.

Important information

Infection prevention can continue after treatment because immune suppression may be prolonged. Tell any transfusion service about prior fludarabine exposure because irradiated blood components may be required.